Everolimus
mTOR inhibitor; Autophagy modulator. Inhibits SARS-CoV in silico, and MERS-CoV in cells. Laise et al. bioRxiv, May 17 2020, https://doi.org/10.1101/2020.05.12.091256; Zumla et al. Nat. Rev. Drug Discov. 15:327–347 2016, https://dx.doi.org/10.1038/nrd.2015.37.
- Datasheet: view or download
- Applications:Approved drug (U.S.) that could be repurposed
Biochemicals & reagents
159351-69-6
1) Schuurman et al. (1997), SDZ RAD, a new rapamycin derivative: synergism with cyclosporine; Transplantation, 64 32 2) Neuhaus et al. (2001), mTOR inhibitors: an overview; Liver Transpl., 7 473 3) Kahan et al. (2002), Therapeutic drug monitoring of immunosuppressant drugs in clinical practice; Clin. Ther., 24 330
958.25
-20°C
Everolimus is a semisynthetic analog of rapamycin with potent immunosuppressive activity (1) and inhibits mTOR2 . This compound is clinically useful as an immunosuppressant (3).